QL1706 with chemo and anlotinib for recurrent ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that is epithelial type (the most common kind).
- Your cancer came back after platinum-based chemo, either at least 6 months later (platinum-sensitive) or within 6 months (platinum-resistant).
- You are between 18 and 70 years old.
- You have at least one tumor that can be measured on a scan.
- You have not had any prior immunotherapy (like PD-1 or PD-L1 inhibitors) or certain other targeted drugs (like anlotinib).
- You do not have serious health problems such as uncontrolled infections, major heart or lung disease, or a history of certain autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy for women with advanced or recurrent endometrial cancer that hasn't been treated yet. It may help shrink or control the cancer.
This trial tests a new treatment called QL1706 for people with cervical cancer that has come back or spread and has not responded to platinum-based chemotherapy. It aims to see if QL1706 can help shrink tumors and improve outcomes.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Treatment of Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.